11 articles for thisTarget

---

The following articles (labelled with PubMed ID or TBD) are for your review

PMID	Data	Article Title	Organization
26393374	34	Improving the Selectivity of Engineered Protease Inhibitors: Optimizing the P2 Prime Residue Using a Versatile Cyclic Peptide Library.	Queensland University of Technology
24211642	49	Identification by in silico and in vitro screenings of small organic molecules acting as reversible inhibitors of kallikreins.	Universit£
23849879	23	1,2,4-Triazole derivatives as transient inactivators of kallikreins involved in skin diseases.	Universit£
30691925	34	Kallikrein 5 inhibitors identified through structure based drug design in search for a treatment for Netherton Syndrome.	Glaxosmithkline R&D
31521475	205	Design and development of a series of borocycles as selective, covalent kallikrein 5 inhibitors.	Glaxosmithkline
31005442	64	Structure guided drug design to develop kallikrein 5 inhibitors to treat Netherton syndrome.	Glaxosmithkline R&D
30888159	18	Amino Acid Scanning at P5' within the Bowman-Birk Inhibitory Loop Reveals Specificity Trends for Diverse Serine Proteases.	The University of Queensland
30613336	32	Potent, Selective, and Cell-Penetrating Inhibitors of Kallikrein-Related Peptidase 4 Based on the Cyclic Peptide MCoTI-II.	The University of Queensland
30212625	107	Depsipeptides Featuring a Neutral P1 Are Potent Inhibitors of Kallikrein-Related Peptidase 6 with On-Target Cellular Activity.	German Cancer Research Center (Dkfz)
29517911	87	Stable and Long-Lasting, Novel Bicyclic Peptide Plasma Kallikrein Inhibitors for the Treatment of Diabetic Macular Edema.	Bicycle Therapeutics